Morgan Stanley
CMMB

Morgan Stanley’s Chemomab Therapeutics CMMB Stock Holding History

Morgan Stanley’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.79K Sell
3,575
-1,000
-22% -$1.69K ﹤0.01% 7175
2026
Q1 		$7.18K Buy
4,575
+800
+21% +$1.37K ﹤0.01% 7042
2025
Q4 		$6.23K Sell
3,775
-86,290
-96% -$229K ﹤0.01% 7012
2025
Q3 		$237K Sell
90,065
-313,469
-78% -$1.16M ﹤0.01% 5824
2025
Q2 		$1.87M Buy
403,534
+374,244
+1,278% +$1.85M ﹤0.01% 4741
2025
Q1 		$128K Buy
29,290
+3,190
+12% +$22.4K ﹤0.01% 5909
2024
Q4 		$189K Sell
26,100
-74,468
-74% -$470K ﹤0.01% 5804
2024
Q3 		$632K Buy
100,568
+98,768
+5,487% +$554K ﹤0.01% 5292
2024
Q2 		$6.57K Buy
1,800
+1,101
+158% +$3.81K ﹤0.01% 6785
2024
Q1 		$2.18K Sell
699
-17,030
-96% -$43.8K ﹤0.01% 7052
2023
Q4 		$36.2K Buy
+17,729
New +$46.7K ﹤0.01% 6267
2023
Q3 		– Sell
-25
Closed -$132 – 7627
2023
Q2 		$132 Sell
25
-1,925
-99% -$12.1K ﹤0.01% 7481
2023
Q1 		$12.4K Buy
1,950
+300
+18% +$2.35K ﹤0.01% 6807
2022
Q4 		$21.1K Buy
1,650
+100
+6% +$863 ﹤0.01% 6677
2022
Q3 		$15K Buy
1,550
+151
+11% +$1.95K ﹤0.01% 6915
2022
Q2 		$21K Buy
+1,399
New +$19.5K ﹤0.01% 6952
2022
Q1 		– Sell
-2,911
Closed -$80K – 7980
2021
Q4 		$80K Buy
2,911
+2,887
+12,029% +$102K ﹤0.01% 6566
2021
Q3 		$1K Sell
24
-17
-41% -$1.03K ﹤0.01% 7760
2021
Q2 		$3K Sell
41
-43
-51% -$4.2K ﹤0.01% 7481
2021
Q1 		$10K Sell
84
-43
-34% -$8.56K ﹤0.01% 6931
2020
Q4 		$14K Buy
+127
New +$12.2K ﹤0.01% 6543
2019
Q4 		– Sell
-170
Closed -$25K – 6657
2019
Q3 		$25K Buy
+170
New +$33.1K ﹤0.01% 5942

Other funds holding CMMB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
PIP
Philadelphia Investment Partners Voorhees, New Jersey $161M AUM
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Morgan Stanley's CMMB Position: Q2 2026 in Review

Morgan Stanley reduced its Chemomab Therapeutics (CMMB) stake by 22% in Q2 2026, selling an estimated $1.69K and leaving 3,575 shares worth $5.79K. The position accounts for ﹤0.01% of the portfolio, ranked #7175.

Morgan Stanley first reported a position in CMMB in Q3 2019 and has held it in 22 quarters since. The position peaked at $1.87M in Q2 2025. 13 funds tracked by Wall St. Rank hold CMMB as of Q2 2026.

  • Morgan Stanley held 3,575 shares of Chemomab Therapeutics worth $5.79K as of Q2 2026.
  • Morgan Stanley sold 1,000 Chemomab Therapeutics shares in Q2 2026, an estimated $1.69K.
  • Chemomab Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7175 holding.
  • Morgan Stanley first reported a position in Chemomab Therapeutics in Q3 2019 and has held it in 22 quarters since.
  • Morgan Stanley's Chemomab Therapeutics position peaked at $1.87M in Q2 2025.
  • 13 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.